Skip Navigation

European Heart Journal 2004 25(4):281-282; doi:10.1016/j.ehj.2003.12.013
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Givertz, M. M.
Right arrow Articles by Braunwald, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Givertz, M. M.
Right arrow Articles by Braunwald, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Neurohormones in heart failure: predicting outcomes, optimizing care

Michael M. Givertz and Eugene Braunwald*

Cardiovascular Division, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, USA

* Correspondence to: Eugene Braunwald, MD, TIMI Study Group, 350 Longwood Avenue First Floor, Boston MA 02115, USA. Tel: 617-732-8989; Fax: 617-975-0955
E-mail address: ebraunwald@partners.org

Received 11 December 2003; accepted 12 December 2003

The first 10% of the full text of this article appears below.

This editorial refers to ''The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT'' by R. Latini et al. on page 292{dagger}

As both the prevalence of heart failure (HF) and the number of therapeutic modalities for this condition grow, the search for improved biomarkers to predict prognosis and guide therapy continues. In this issue of the European Heart Journal, Latini et al.1report on the relative prognostic value of plasma neurohormones in HF by analysing the relationship between six biomarkers and outcomes in 4300 patients in the Valsartan in Heart Failure Trial (Val-HeFT). Although on univariate analysis all six neurohormones (Endothelin-1, Big Endothelin-1, aldosterone, plasma renin activity (PRA), B-type natriuretic peptide . . . [Full Text of this Article]

1. Neurohormonal activation and outcomes in heart failure

2. Should reducing PNE be a goal of therapy?

3. Limitations of measuring PNE

4. Natriuretic peptides: initial observations and prognostic value

5. Can BNP predict the response to therapy?

6. Practical considerations in measuring BNP

7. Conclusions


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT
Roberto Latini, Serge Masson, Inder Anand, Monica Salio, Allen Hester, Dianne Judd, Simona Barlera, Aldo P Maggioni, Gianni Tognoni, Jay N Cohn, and for the Val-HeFT Investigators
EHJ 2004 25: 292-299. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 HeartHome page
C Philippe, M Stoica-Herman, X Drouot, B Raffestin, P Escourrou, L Hittinger, P-L Michel, S Rouault, and M-P d'Ortho
Compliance with and effectiveness of adaptive servoventilation versus continuous positive airway pressure in the treatment of Cheyne-Stokes respiration in heart failure over a six month period
Heart, March 1, 2006; 92(3): 337 - 342.
[Abstract] [Full Text] [PDF]